Donga Socio Holdings to Absorb Donga Pharmaceutical and Transition to an Operating Holding Company Structure

Small-scale Merger of Wholly-owned Subsidiary Scheduled for October 1
Simplified Governance Structure, Faster Investment Decisions
Expected to Resolve Holding Company Discount and Enhance Corporate Value

Donga Socio Holdings will absorb its wholly-owned subsidiary, Donga Pharmaceutical, and transition to an “operating holding company” structure.

Dong-A Socio Holdings Dong-A Pharmaceutical building view. Dong-A Socio Holdings

On July 23, Donga Socio Holdings announced that its board of directors has approved the merger with Donga Pharmaceutical. The merger date is set for October 1, 2026.

This merger will proceed as a small-scale merger without issuing new shares. Since Donga Pharmaceutical is a wholly-owned subsidiary, there will be no change in the shareholder composition or shareholding ratio of Donga Socio Holdings after the merger.

The integrated entity plans to leverage Donga Pharmaceutical’s brand and distribution infrastructure to expand its e-commerce channels, enter global retail chains, pursue brand collaborations, and strengthen its overseas consumer healthcare business.

A representative of Donga Socio Holdings stated, “This merger is a strategic decision to become a global healthcare company, building on our accomplishments in converting to a holding company.” They added, “We will increase investment to secure new growth engines and enhance both our corporate and shareholder value.”

This content was produced with the assistance of AI translation services.